Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.53  0.05  1.94%   
About 61% of Lisata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at news.google.com         
Lisata Therapeutics to Present at BIO CEO Investor Conference - Yahoo Finance
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Autologous Cell Therapy Global Research Report 2024 Market to Surge to 19.53 Billion by 2028, Propel...
Yahoo News
over six months ago at news.google.com         
Lisata Stock Up More Than 35 percent in 3 Months Heres Why - Zacks Investment Research
Google News at Macroaxis
over six months ago at benzinga.com         
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with ...
benzinga news
over six months ago at thelincolnianonline.com         
Celebrus Technologies Buy Rating Reiterated at Canaccord Genuity Group
news
over six months ago at investing.com         
Assembly Biosciences sees major stock purchase by investor Alexander Schornstein
Investing News at Macroaxis
over six months ago at thelincolnianonline.com         
Lisata Therapeutics Rating Reiterated by HC Wainwright
news
over six months ago at finance.yahoo.com         
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gast...
Yahoo News
over a year ago at benzinga.com         
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastat...
benzinga news
over a year ago at thelincolnianonline.com         
Celebrus Technologies Stock Rating Reaffirmed by Canaccord Genuity Group
news
over a year ago at news.google.com         
Lisata Therapeutics to Present at NobleCon19 Investor Conference - Marketscreener.com
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Lisata Therapeutics to Present at NobleCon19 Investor Conference
Yahoo News
over a year ago at thelincolnianonline.com         
Celebrus Technologies Receives Not Rated Rating from Shore Capital
news
over a year ago at thelincolnianonline.com         
Celebrus Technologies plc Announces Dividend of GBX 0.92
news
over a year ago at benzinga.com         
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
benzinga news
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635
11/21/2024
2
Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases
12/06/2024
3
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
12/10/2024
4
Why Pacific Biosciences of California Is the Worst ARK Stock to Buy According to Short Sellers
12/11/2024
5
Riassunto Parse Biosciences lancia Evercode Mouse BCR per supportare la progettazione e lo sviluppo di anticorpi per applicazioni di scoperta di farmaci
12/12/2024
6
Parse Biosciences lana BCR para ratos a fim de apoiar a engenharia e o desenvolvimento de anticorpos para aplicaes de descobrimento de medicamentos
12/13/2024
7
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the ...
12/16/2024
8
Xenetic Biosciences, Inc. Releases Virtual Investor What This Means Segment
12/17/2024

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance